Ertugliflozin pidolate

In November, the pharmaceutical industry experienced significant changes in executive personnel, with adjustments at several well-known domestic and international enterprises drawing widespread attention. These changes not only reveal internal strategic adjustments but also signal new trends for the industry's future development. Bristol-Myers Squibb (BMS) recently announced further layoffs as part of its cost-saving strategy. According to the New Jersey Worker Adjustment and Retraining Notification (WARN) document, this round of layoffs affects 195 employees. This is part of BMS's layoff plan in the Lawrenceville area, which follows the announcement in May of a reduction of 963 positions, bringing the total layoffs in the area to 1,329. These measures are crucial to BMS's plan to achieve a cost-saving target of $1.5 billion by the end of 2025. BMS emphasizes that through layoffs and process optimization, the company can allocate resources more effectively and focus on investing in innovative drugs and transformative treatment solutions, aiming to create greater value for patients and shareholders. A company spokesperson noted that BMS is committed to optimizing its operational structure and prioritizing funding for innovative drug development that maximizes patient welfare and shareholder returns. At the same time, it was reported that Merck is also laying off employees in its diabetes business division in China to respond flexibly to market fluctuations and business restructuring needs. This move may relate to the increasingly fierce competition in centralized procurement and generic drugs in the Chinese market. Merck's main products in the diabetes market in China include sitagliptin, sitagliptin/metformin, and ertugliflozin. Although the specific scale of the layoffs has not been publicly disclosed, the market generally believes this is related to intensified price competition under centralized procurement policies. Notably, sitagliptin and its combination formulations have been included in the national centralized procurement list, placing significant pressure on Merck's market share in China. Sales data illustrate the pressure Merck faces. In 2022, sitagliptin and its metformin combination formulations contributed $4.513 billion in sales to Merck; however, by 2023, this total had declined to $3.366 billion. For example, sitagliptin tablets have seen over 30 companies participating in the development and production of generics in the Chinese market, resulting in fierce competition. On November 18, reports emerged that Johnson & Johnson China is undergoing layoffs across multiple product lines, with compensation plans offering "N+1," "N+2," and "N+3" based on years of service. Johnson & Johnson China has yet to officially respond to this news. It is reported that the scale of these layoffs could reach 20% of the total workforce, primarily focused on the surgical department. Some affected employees revealed that layoff notifications were sent via private email, with departure dates set for the end of this year. This round of layoffs may be related to pressures from centralized procurement in surgery and the company's strategic adjustments. Notably, Johnson & Johnson Medical Technology recently announced a major organizational restructuring of its surgical division, which will be reorganized into six major departments starting January 1, 2025. Additionally, the departure of the Senior Director of the MONARCH Surgical Division in China, Chen Xiaoming, further confirms the ongoing changes within the company. In addition to BMS, Merck, and Johnson & Johnson, changes in executive personnel at other domestic pharmaceutical companies continue to attract industry attention, including the resignation of the chairman of Tianjin Pharmaceutical Daren Tang, the appointment of a new chairman at Guangyao Group, the appointment of a new vice president at Health元, the replacement of the general manager at Sinopharm Yisheng, the resignation of a vice president at Kanghua Bio, the replacement of the CEO at Saint No Pharmaceuticals, and the resignation of a director at Zhejiang Zhenyuan. These changes will undoubtedly introduce more uncertainties and observation points for the future development of the pharmaceutical industry.

裁员仍在持续。 据药研网统计，11月宣布减员的药企数量为17家，相比去年减少11%。 其中，默克、强生正在中国进行裁员，加剧了国内制药市场动荡。 2024年11月裁员汇总 赛默飞运营优化，裁员160名员工 11月7日, 据WARN, 赛默飞将在马萨诸塞州裁员160人，到2026年11月解雇列克星敦、普兰维尔和剑桥的员工，关闭列克星敦工厂。据赛默飞解释，裁员与其评估其全球运营，调整人员配置，进行项目转移有关。  23andMe停止所有治疗项目，裁员40% 据ENDPOINTSNEWS报道，基因检测公司 23andMe 于11月11日表示，将关闭其治疗部门，并将逐步结束正在进行的临床试验。业务重组的同时，简化运营，大幅裁掉超过200个职位，约占其总员工的40%。专注于其基因检测服务和产品，预计此举将带来每年超过3500万美元的成本节省。 吉利德总部裁员超百人，并解雇多名高管 据WARN,吉利德上周计划关闭西雅图办事处并裁员 72 人，并透露从 2025 年 3 月开始在加州总部裁员 104 个职位。该裁员计划包括解雇 5 名副总裁、1 名高级副总裁和公共事务、风险治理和人力资源等领域的董事。 强生中国业务重组，裁员超2000人 据彭博社报道，强生正在中国裁员，裁员主要影响销售外科产品的部门，本轮中国裁员，可能与外科集采压力、公司战略调整等因素有关。 据第一财经全球的报告指出，强生的裁员行动是其在中国业务重组计划的一环，波及了“多个部门”的职员，主要影响的是手术产品线的销售部门。强生的裁员人数占其大陆员工的五分之一多。据其网站称，J&J 在中国约 90 个城市拥有近 10,000 名员工。 强生公司发言人在一封电子邮件中告诉彭博社，“最近实施了组织变革以优化我们在中国的业务运营”。并补充说，仍致力于“关键且不断增长的”中国市场。 Merck面临仿制药竞争，利润率下降 据彭博社报道，默克的裁员在很大程度上影响了其在中国的糖尿病团队。该公司在中国销售糖尿病药物 Janumet、Januvia 和 Steglatro。由于在某些市场与仿制药竞争对手竞争，这些治疗药物的全球销量正在下降。 裁员也是在该公司应对中国对 HPV 疫苗 Gardasil 的需求迅速下降之际发生的，这导致第三季度超级重磅疫苗的销量同比下滑 11%。 百时美施贵宝总部裁员195人 为了节约成本，优先考虑新药，BMS正在美国总部裁员195名员工。BMS 证实了此次裁员，公布计划减少管理层并简化整个公司的决策。预计 2024 年将裁减约 2,200 个职位，使员工人数减少 6%。 此举旨在到 2025 年底将成本降低 15 亿美元，BMS表示优先考虑具有最大投资回报潜力的研发项目, 目前Eliquis 和 Opdivo 等产品销售强劲提振了营收，削减成本计划似乎已奏效。  Alector AD药物II期研发失败，裁员17% Alector公司与艾伯维合作的阿尔茨海默病药物AL002 2 期试验失败，对疾病进展或生物标志物无显著影响。据结果，Alector 将停止长期扩展研究。为了集中资源，Alector裁员 17%。 诺华品牌策略转变，裁员上百人  据WARN，诺华将在公司美国总部所在地新泽西州东汉诺威裁员 139 人。裁员将主要影响负责治疗哮喘和过敏的品牌 Xolair 以及由激酶抑制剂 Tafinlar 和 Mekinist (Taf+Mek) 组成的肿瘤组合的商业现场销售人员。 癌症组合已获批用于某些黑色素瘤、非小细胞肺癌、甲状腺癌和其他恶性肿瘤患者。据诺华解释，裁员主要因为品牌策略的转变。 Medigene 大幅裁员40%  11月26日，Medigene启动了重组，计划大幅裁员约40%，集中资源开发 T 细胞受体（TCR）引导的疗法，使其现金跑道维持到 2025 年 7 月，该生物技术公司还将优先与药明生物合作，开发其 TCR 引导的 T 细胞接合MDG3010。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。 转载/商务/投稿 | 联系微信15618157102（sum_Gmi） 商务合作 稿件征集 点击了解详情 往期回顾 1 10月 | 20家生物医药裁员汇总 2 国产首款四价HPV疫苗拟纳入优先审评 3 3. 7亿美元!今年规模最大的生物医药融资诞生